ClinicalTrials.govpublic full text
Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy
cancer, skin disease, immunotherapy, patients with solid tumors receiving immunotherapy with an ici will be randomized to participate in an sdoh and side effects navigation program vs. control, checkpoint inhibitor, immuno-oncology, cutaneous adverse events, observational
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 806141
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.